SCHEMBL24674322

SCHEMBL24674322

Oc1nc(O)c2cc(Br)cnc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1B Q9Y463 10/20 0.41
DYRK1A Q13627 5/20 0.41
CHEK1 O14757 2/20 0.41
AURKA O14965 1/20 0.41
DAPK3 O43293 1/20 0.41
JAK2 O60674 1/20 0.41
MAP4K4 O95819 1/20 0.41
PAK4 O96013 1/20 0.41
ABL1 P00519 1/20 0.41
CSF1R P07333 1/20 0.41
RET P07949 1/20 0.41
IGF1R P08069 1/20 0.41
FGFR1 P11362 1/20 0.41
PDGFRA P16234 1/20 0.41
PRKACA P17612 1/20 0.41
FLT1 P17948 1/20 0.41
LTK P29376 1/20 0.41
GRK5 P34947 1/20 0.41
KDR P35968 1/20 0.41
CSNK1A1 P48729 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25305800 0.81 SMN1; SMN2 (0.46) DYRK1BDYRK1ACHEK1AURKADAPK3
SCHEMBL30103920 0.81 SMN1; SMN2 (0.46) DYRK1BDYRK1ACHEK1AURKADAPK3
SCHEMBL4072522 0.81 DYRK1B (0.46) DYRK1BDYRK1ACHEK1AURKADAPK3
SCHEMBL30492388 0.77 GUSB (0.36) DYRK1AHTTMAPK1IDO1HRH4
SCHEMBL25304094 0.77 GUSB (0.36) DYRK1AHTTMAPK1IDO1HRH4
SCHEMBL31138368 0.77 KDM4E (0.39)
SCHEMBL2171113 0.77
SCHEMBL13686494 0.74 DYRK1B (0.42) DYRK1BDYRK1ACHEK1AURKADAPK3
SCHEMBL25306400 0.73 DYRK1B (0.41) DYRK1BDYRK1ACHEK1AURKADAPK3
SCHEMBL3455768 0.73 CHEK1 (0.36) DYRK1BDYRK1ACHEK1AURKADAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606562-B2 Pyridopyrimidines derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-04-21 US disclosed
CN-116731038-A Nitrogen-containing heterocyclic compound, and preparation method and application thereof 苏州亚盛药业有限公司 2023-09-12 CN disclosed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 US disclosed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 US disclosed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 US disclosed
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2022-07-28 US disclosed
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2022-07-28 US disclosed
CN-114222741-A As P2X3Suppression ofPyridopyrimidine derivatives as agents 奇斯药制品公司 2022-03-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 DYRK1B 2735/4885DYRK1A 2677/4885CHEK1 4011/4885
US-12606562-B2 Pyridopyrimidines derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX2 DYRK1B 2916/4885DYRK1A 2743/4885CHEK1 3460/4885
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 DYRK1B 2735/4885DYRK1A 2677/4885CHEK1 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.